(A) Chemical structure of SB431542, an inhibitor of Tgfbr1 activity.
(B) Inhibition of Tgf-β signaling by treatment of Oct4, cMyc, and Sox2-infected MEFs with SB431542 or TGF-β neutralizing antibodies replaces Sox2.
(C) RepSox does not increase the efficiency of Oct4∷GFP+ colony induction in Oct4, Klf4, cMyc, and Sox2-infected MEFs.
(D) Inhibition of Tgf-β signaling by TGF-β neutralizing antibodies does not increase the efficiency of Oct4∷GFP+ colony induction in Oct4, Klf4, cMyc, and Sox2-infected MEFs.
(E) RepSox does not replace transgenic Oct4 or transgenic Klf4 in reprogramming. We observed no Oct4∷GFP+ colonies in RepSox-treated Klf4, cMyc, Sox2-infected MEFs or Oct4, cMyc, Sox2-infected MEFs out of 30,000 cells plated both with and without VPA treatment. We routinely observe 30-40 Oct4∷GFP+ colonies when we plate the same number of Oct4, Klf4, cMyc-infected MEFs and treat with RepSox.
(F) RepSox can replace cMyc in reprogramming. Cells were transduced with Oct4, Klf4, and cMyc and treated with RepSox continuously starting at day 5 post-infection.
(G) Inhibition of Tgf-β signaling can replace cMyc in reprogramming. Cells were transduced with Oct4, Klf4, and cMyc and treated with inhibitors of Tgf-β signaling continuously starting at day 5 post-infection.